Hyperkalemia exposure impairs EDHF-mediated endothelial function in the human coronary artery

Annals of Thoracic Surgery

Volumn 63, Issue 1, 1997, Pages 84-87

  He, Guo Wei ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; CALCIMYCIN; CALCIUM IONOPHORE; INDOMETACIN; N(G) NITROARGININE;

ARTICLE; CARDIOPLEGIA; CONTROLLED STUDY; CORONARY ARTERY DISEASE; ENDOTHELIUM; ENDOTHELIUM INJURY; HUMAN; HUMAN TISSUE; HYPERKALEMIA; PRIORITY JOURNAL;

15-HYDROXY-11 ALPHA,9 ALPHA-(EPOXYMETHANO)PROSTA-5,13-DIENOIC ACID; BIOLOGICAL FACTORS; CALCIMYCIN; CORONARY VESSELS; ENDOTHELIUM, VASCULAR; HUMANS; HYPERKALEMIA; INDOMETHACIN; POTASSIUM; PROSTAGLANDIN ENDOPEROXIDES, SYNTHETIC; THROMBOXANE A2; VASOCONSTRICTOR AGENTS; VASODILATION;

EID: 0031031855     PISSN: 00034975     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0003-4975(96)00681-9     Document Type: Article

References (25)

1. Saldanha C, Hearse DJ. Coronary vascular responsiveness to 5-hydroxytryptamine before and after infusion of hyperkalemic crystalloid cardioplegic solution in the rat heart. Possible evidence of endothelial damage. J Thorac Cardiovasc Surg. 98:1989;783-787.
2. Evora PRB, Pearson PJ, Schaff HV. Crystalloid cardioplegia and hypothermia do not impair endothelium-dependent relaxation or damage vascular smooth muscle of epicardial coronary arteries. J Thorac Cardiovasc Surg. 104:1992;1365-1374.
3. He G-W, Yang C-Q, Wilson GJ, Rebeyka IM. Tolerance of coronary endothelium and smooth muscle to hyperkalemia. Ann Thorac Surg. 57:1994;682-688.
4. He G-W, Yang C-Q, Rebeyka IM, Wilson GJ. Effects of hyperkalemia on neonatal endothelium and smooth muscle. J Heart Lung Transplant. 14:1995;92-101.
5. Nilsson FN, Miller VM, Vanhoutte PM, McGregor CGA. Methods of cardiac preservation alter the function of the endothelium in porcine coronary arteries. J Thorac Cardiovasc Surg. 102:1991;923-930.
6. He G-W, Yang C-Q. Hyperkalemia alters endothelium-dependent relaxation through non-nitric oxide and noncyclooxygenase pathway a mechanism for coronary dysfunction due to cardioplegia . Ann Thorac Surg. 61:1996;1394-1399.
7. He G-W, Yang C-Q, Graier WF, Yang J-A. Hyperkalemia alters EDHF-mediated hyperpolarization and relaxation in coronary arteries. Am J Physiol. 271 (Heart Circ Physiol 40):1996;H760-7.
8. Hecker M, Bara AT, Bauersachs J, Busse R. Characterization of endothelium-derived hyperpolarizing factor as a cytochrome P450-derived arachidonic acid metabolite in mammals. J Physiol. 481:1994;407-414.
9. Feletou M, Vanhoutte PM. Endothelium-dependent hyperpolarization of canine coronary smooth muscle. Br J Pharmacol. 93:1988;515-524.
10. Chen G, Suzuki H, Weston AH. Acetylcholine releases endothelium-derived hyperpolarizing factor and EDRF from rat blood vessels. Br J Pharmacol. 95:1988;1165-1174.
11. Taylor SG, Weston AH. Endothelium-derived hyperpolarizing factor a new endogenous inhibitor from the vascular endothelium . Trends Pharmacol Sci. 9:1988;72-74.
12. Nagao T, Vanhoutte PM. Hyperpolarization contributes to endothelium-dependent relaxations to acetylcholine in femoral veins of rats. Am J Physiol. 261(Heart Circ Physiol 30):1991;H1034-7.
13. Chen G, Yamamoto Y, Miwa K, Suzuki H. Hyperpolarization of arterial smooth muscle induced by endothelial humoral substances. Am J Physiol. 260(Heart Circ Physiol 29):1991;H1888-92.
14. Holzmann S, Kukovetz WR, Windischhofer W, Paschke E, Graier WF. Pharmacologic differentiation between endothelium-dependent relaxations sensitive and resistant to nitro-L-arginine in coronary arteries. J Cardiovasc Pharmacol. 23:1994;747-756.
15. Brayden JE. Membrane hyperpolarization is a mechanism of endothelium-dependent cerebral vasodilation. Am J Physiol. 259(Heart Circ Physiol 28):1990;H668-73.
16. He G-W, Angus JA, Rosenfeldt FL. Reactivity of the canine isolated internal mammary artery, saphenous vein, and coronary artery to constrictor and dilator substances relevance to coronary bypass graft surgery . J Cardiovasc Pharmacol. 12:1988;12-22.
17. 1-adrenoceptor mediated contraction in the human internal mammary artery. J Cardiovasc Pharmacol. 21:1993;256-263.
18. He G-W, Buxton B, Rosenfeldt F, Angus JA. Reactivity of human isolated internal mammary artery to constrictor and dilator agents. Implications for treatment of internal mammary artery spasm. Circulation. 80(Suppl 1):1989;I141-50.
19. He G-W, Acuff TE, Yang C-Q, Ryan WH, Mack MJ. Functional comparison between the human inferior epigastric artery and internal mammary artery similarities and differences . J Thorac Cardiovasc Surg. 109:1995;13-20.
20. Siegel G, Ruckborn K, Schnalke F, Muller J. Endothelial disfunction in human atherosclerotic coronary arteries. Eur Heart J. 14(Suppl 1):1993;99-103.
21. He G-W, Yang C-Q, Starr A. An overview of the nature of vasoconstriction in arterial grafts for coronary surgery. Ann Thorac Surg. 59:1995;676-683.
22. Sato H, Zhao ZQ, McGee DS, Williams MW, Hammon JW Jr, Vinten-Johansen J. Supplemental L-arginine during cardioplegic arrest and reperfusion avoids regional postischemic injury. J Thorac Cardiovasc Surg. 110:1995;302-314.
23. Stein DG, Permut LC, Drinkwater DC Jr, et al. Complete functional recovery after 24-hour heart preservation with University of Wisconsin solution and modified reperfusion. Circulation. 84(Suppl 3):1991;316-323.
24. Jeevanandam V, Barr ML, Auteri JS, et al. University of Wisconsin solution versus crystalloid cardioplegia for human donor heart preservation. A randomized blinded prospective clinical trial. J Thorac Cardiovasc Surg. 103:1992;194-199.
25. Aeba R, Keenan RJ, Hardesty RL, Yousem SA, Hamamoto I, Griffith BP. University of Wisconsin solution for pulmonary preservation in a rat transplant model. Ann Thorac Surg. 53:1992;240-246.